BEL after RTX targets IgA2 anti-dsDNA abs and favors formation of anergic/resting B cells while reducing potentially pathogenic B-cell subsets. Abs 0978 #ACR22 @RheumNow https://t.co/Y798OAwtbt https://t.co/IfXOv67MLV
Links:
Belimumab After Rituximab Targets IgA2 Anti-dsDNA Antibody Production and Shift…
http://ow.ly/ySnF50LyKzB
13-11-2022